Etomoxir and orlistat inhibit cell cycle progression and decreased proliferation rate in myeloma cells.

<p>The effect of etomoxir and orlistat on cell cycle phases was determined in myeloma cells preincubated in the presence or absence of 50 µM etomoxir or 20 µM orlistat for 18 or 24 hours respectively as described in “<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046484#s4" target="_blank">Materials and Methods</a>” section. (<b>A,B</b>) Cell cycle phases in U-266B1 cells. (<b>C,D</b>) Cell cycle phases in NCI-H929 cells. Results are means ± SEM for 3 independent experiments in triplicate. *p<0.05 versus untreated cells. The effect of 50 µM etomoxir (<b>E</b>), 20 µM orlistat (<b>F</b>) on the proliferation rate in RPMI-8226, U-266B1 and NCI-H929 cells was determined by the incorporation of tritiated thymidine assay. Results are means ± SEM for 3–6 independent experiments in triplicate. *p<0.05 versus untreated cells. The effect of 50 µM etomoxir, 20 µM orlistat or the combination of both drugs on the proliferation rate in U-266B1 cells (<b>G</b>) and RPMI-8226 cells (<b>H</b>) was determined by the incorporation of tritiated thymidine assay. Results are means ± SEM for 3–6 independent experiments in triplicate. *p<0.05 versus untreated cells. ^#p<0.05 versus etomoxir and orlistat treated cells.